Vitamin K2 form, oral supplement

Vitamin K2 (MK-7)

Vitamin K2 (MK-7) is listed in the app with a half-life of about 72 hours, and the authors of the AVADEC trial cite 68 hours for MK-7.1

Moderate evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Vitamin K2 (MK-7) after one dose: 50% at ~72 h, 25% at 144 h, 12.5% at 216 h.

Drawn from the half-life in the app's model, ~72 h. The model's figures

Menaquinone-7 (MK-7) is a form of vitamin K2 that, in the words of a United States Pharmacopeial Convention safety review, "occurs naturally in some animal-derived and fermented foods" and is "also available as an ingredient of dietary supplements".2 The review's authors work at the US Pharmacopeial Convention, and they conclude that MK-7, "when ingested as a dietary supplement, is not associated with any serious risk to health or with other public health concerns".2

Schurgers and colleagues, in Blood in 2007, compared vitamin K1 with natto-derived MK-7 in healthy volunteers, and describe vitamin K as "a cofactor in the production of blood coagulation factors (in the liver), osteocalcin (in bone), and matrix Gla protein (cartilage and vessel wall)".3 The introduction to the 2013 Knapen trial opens with "contradictory data on vitamin K supplementation and bone health".4

The app grades the evidence for vitamin K2 (MK-7) as moderate.

2

How it works

The VitaK-CAC registry entry, from Maastricht University Medical Center, states that matrix Gla protein (MGP) "requires Vitamin K-mediated carboxylation to function properly".5 The same entry gives, as part of its rationale, that "In animal studies, active supplementation of Vitamin K2 caused regression of existing arterial calcification", which is an animal result and not a result in people.5 The AVADEC authors measured dephosphorylated-undercarboxylated MGP (dp-ucMGP) because "a normal range of plasma vitamin K does not exist", and used it "as a proxy of vitamin K deficiency".1

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~72 h
Bioavailability
80%
Typical dose
90–200 mcg/day
Route
Oral
Time to peak
~6 h

The second column of the table holds the app's own figures, shown beside what the sources report.

Table 3.1Half-life and pharmacokinetics4 rows
ParameterApp's figureReported in the sources
Half-life~72 hCalled "very long" by Schurgers and colleagues in healthy volunteers and by Du and colleagues in two single-dose studies in healthy men; the AVADEC authors give 68 hours for MK-7, against 1 to 2 hours for vitamin K13,6,1
Time to peak~6 hPeak serum concentrations 4 hours after intake of vitamin K1 or MK-7 in Schurgers and colleagues; peak plasma concentrations at about 6 h after a single 1 mg dose in Du and colleagues3,6
Bioavailability80%The US Pharmacopeial Convention review says MK-7 "has greater bioavailability than other forms of vitamin K"; the AVADEC authors give absorption of MK-7 as 100%, against 5% to 10% for vitamin K1; none of the records read states 80%2,1
AccumulationNot an app figureMK-7 accumulated to levels 7- to 8-fold higher during prolonged intake in healthy volunteers3

Du and colleagues (Chonggang General Hospital, Chongqing, with co-authors at Chongqing Denali Medpharma and Guangdong Sungen Biotech) reported, in the British Journal of Nutrition in 2023, two randomised single-dose, open, one-way trials in 5 and 12 healthy men.6 The PubMed record gives no funder and no half-life value in numbers.6 The Schurgers authors are listed at VitaK and the Cardiovascular Research Institute Maastricht, University of Maastricht, and the PubMed record of that 2007 paper gives no number of volunteers, dose or funder.3

Level over 6 weeks

Interval between doses

Level, as a share of the peak after one 100 mg dose

As studied: once daily, as in the Knapen trial4.

An illustration from a pharmacokinetic model using a half-life of 72 hours (3 days). It is not a measured level or a suggested dose.

4

Human studies

The table lists the randomised trials and the one meta-analysis of MK-7 or vitamin K read for this compound.

Table 4.1Human studies10 rows
Study and yearDesignPeopleDose and lengthMain result
Knapen and colleagues, Osteoporosis International 20134Randomised, placebo-controlled4244 healthy postmenopausal women4180 µg MK-7 daily for 3 years4Smaller age-related decline in bone mineral content and density at the lumbar spine and femoral neck, but not at the total hip; smaller loss of vertebral height at the lower thoracic mid-site4
Knapen and colleagues, Thrombosis and Haemostasis 20157Double-blind, placebo-controlled7244 healthy postmenopausal women (placebo 124, MK-7 120)7180 µg MK-7 daily for 3 years7Carotid-femoral pulse wave velocity and Stiffness Index β decreased in the whole group; dp-ucMGP 50% lower than placebo; no change in acute phase or endothelial dysfunction markers7
Emaus and colleagues, Osteoporosis International 20108Randomised, double-blind, placebo-controlled; olive oil placebo8334 healthy women aged 50 to 60 years, 1 to 5 years after menopause8360 µg MK-7 as natto capsules for 12 months8No difference in bone loss rates at the total hip or any other site; carboxylated osteocalcin higher and undercarboxylated osteocalcin lower with MK-78
Rønn and colleagues, European Journal of Endocrinology 20169Randomised, placebo-controlled, double-blind9148 postmenopausal women with osteopenia, all given calcium and vitamin D9375 µg MK-7 for 12 months9Tibial trabecular number -0.1 ± 1.9% with MK-7 and -3.5 ± 2.2% with placebo; no significant difference in BMD at any site or in radius microarchitecture9
Rønn and colleagues, Osteoporosis International 202110Randomised, placebo-controlled, double-blind10142 postmenopausal women with osteopenia10375 µg MK-7 daily for 3 years, with vitamin D3 38 µg and calcium 800 mg daily in both groups10BMD decreased at all sites with no difference between MK-7 and placebo; microarchitecture and bone turnover markers similar10
Levy-Schousboe and colleagues, RenaKvit, Nephrology Dialysis Transplantation 202311Multicentre, double-blind, placebo-controlled11123 adults on chronic dialysis (MK-7 61, placebo 62)11360 µg MK-7 daily for 2 years11In the intention-to-treat analysis, 1/3 distal radius BMD loss was accelerated with MK-7 relative to placebo (difference -0.023 g/cm2, 95% CI -0.039 to -0.008), a finding the authors say could not be confirmed in per protocol analysis, while the lumbar spine decrease seen with placebo was prevented with MK-7 (difference 0.050 g/cm2, 95% CI 0.015 to 0.085); 65 of 123 reached the 2-year follow-up11
Zwakenberg and colleagues, American Journal of Clinical Nutrition 201912Randomised, double-blind, placebo-controlled1268 men and women with type 2 diabetes and cardiovascular disease (35 MK-7, 33 placebo)12360 µg MK-7 daily for 6 months12Femoral artery PET activity tended to increase with MK-7 (0.25; 95% CI -0.02 to 0.51; P = 0.06); CT calcification mass did not increase (0.50; 95% CI -0.23 to 1.36; P = 0.18)12
Diederichsen and colleagues, AVADEC, Circulation 20221Randomised, double-blind, multicentre, placebo-controlled1365 men, mean age 71.0 years, with aortic valve calcification1720 µg MK-7 plus 25 µg vitamin D daily for 24 months1AVC score rose 275 AU with MK-7 plus vitamin D and 292 AU with placebo; difference in progression 17 AU (95% CI -86 to 53; P=0.64)1
Vossen and colleagues, VitaK-CAC, JAMA Cardiology 202613Randomised, placebo-controlled; 2 hospitals in the Netherlands13180 symptomatic patients with coronary calcium score 50 to 400 AU13360 µg MK-7 daily for 2 years13Median CAC score 145 to 214 AU with placebo and 135 to 184 AU with MK-7; between-group difference P = .02 after adjustment13
Lees and colleagues, Heart 201914Systematic review and meta-analysis of vitamin K supplementation trials1413 controlled trials (n=2162)14Not given in the PubMed record14Vascular calcification -9.1% (95% CI -17.7 to -0.5; p=0.04); non-significant improvement in vascular stiffness; the authors write that conclusions are limited by small numbers of studies with substantial heterogeneity14

Deeper analysis: the Knapen trials in healthy postmenopausal women

Knapen and colleagues (VitaK, Maastricht University) reported a 3-year trial of 180 µg MK-7 daily in 244 healthy postmenopausal women in Osteoporosis International in 2013, measuring bone density at the lumbar spine, total hip and femoral neck by DXA and vertebral fractures by DXA vertebral assessment.4 The authors conclude that "Whether these results can be extrapolated to other populations, e.g., children and men, needs further investigation".4 The PubMed record lists the paper as "Research Support, Non-U.S. Gov't" and gives no funding or conflict statement, and the record text reports no fracture count or adverse event rate.4 A trial in 244 healthy postmenopausal women (placebo 124, MK-7 120) given 180 µg MK-7 daily for three years, reported in Thrombosis and Haemostasis in 2015, states that MK-7 "did not influence the markers for acute phase and endothelial dysfunction".7

Deeper analysis: Rønn and colleagues, osteopenia trials (2016 and 2021)

Rønn and colleagues at Aarhus University Hospital reported, in the European Journal of Endocrinology in 2016, a 12-month trial of MK-7 375 µg in 148 postmenopausal women with osteopenia, all given calcium and vitamin D.9 At 12 months tibial trabecular number was unchanged with MK-7 (-0.1 ± 1.9%) and lower with placebo (-3.5 ± 2.2%), and there were "no significant differences between the groups in HRpQCT-derived parameters at the radius or in BMD at any site".9 The 2021 report in Osteoporosis International covers 142 women with osteopenia given 375 µg MK-7 or placebo daily for 3 years, with vitamin D3 38 µg and calcium 800 mg daily in both groups.10 After 3 years, BMD at the total hip fell by 1.5 ± 2.5% with MK-7 and 2.4 ± 2.7% with placebo, without differences between groups at any site.10 At the femoral neck BMD fell by 1.5 ± 3.5% with MK-7 and 1.0 ± 5.0% with placebo, and at the lumbar spine by 1.8 ± 3.9% and 1.1 ± 3.1% (p > 0.09 for all sites).10 The authors write: "We have previously reported improved microarchitecture with MK-7 after 1 year. However, changes in microstructure over 3 years were similar between the two groups".10 The PubMed records of the two papers carry no funding statement, conflict statement or adverse event data, and the two papers give different numbers of women (148 and 142).9,10

Deeper analysis: RenaKvit

Levy-Schousboe and colleagues reported RenaKvit in Nephrology Dialysis Transplantation in 2023, a multicentre, double-blind, placebo-controlled trial that randomised 123 patients on chronic dialysis to 360 µg MK-7 daily (n = 61) or placebo (n = 62) for 2 years.11 The primary outcome was "changes in BMD of the 1/3 distal radius", which decreased "≈3%" more with MK-7 than with placebo after 2 years (mean difference -0.023 g/cm2, 95% CI -0.039 to -0.008).11 The authors add: "these findings could not be confirmed in per protocol analysis", and that the result "may also be due to a type 1 statistical error in the ITT analysis".11 Among secondary results, "After 2 years, lumbar spine BMD was maintained with MK-7 but decreased significantly with placebo, and changes differed significantly between study groups (P = .005)", while femoral neck, whole body and the other radius sites, bone turnover markers and aortic calcification scores did not differ between groups.11 Twenty-six participants (21%) dropped out in year 1 and 32 more in year 2, and the authors state that "only 30 + 32 patients contributed with 2-year primary outcome data, a number somewhat lower than required according to the power calculations (2 × 49)".11 Adverse events: "A total of 110 participants experienced 968 AEs during the trial and 481 SAEs occurred in 90 participants", and the number of participants with an AE or SAE "did not differ between groups".11 The numbers of participants with bone fracture, parathyroidectomy, a thromboembolic event or death did not differ between groups, but the number of thromboembolic events differed (P = .02) because of more events in one placebo participant.11 The authors conclude that "our findings do not support MK-7 supplementation to preserve bone in patients on dialysis".11 Funders named include the Danish Society of Nephrology, the Danish Kidney Association, the Region Zealand Research Foundation and Kappa Bioscience AS, which also produced the synthetic MK-7 used.11 The conflict statement says the first author's "salary was partially funded by Kappa Bioscience AS, the Danish Society of Nephrology and the Karen Elise Jensen Foundation during the RenaKvit trial", and the funding statement says Kappa Bioscience AS and Orkla Care AS donated tablets but that "neither had further involvement in the study or any part in interpreting the data or acceptance of the results".11

Deeper analysis: Zwakenberg and colleagues, people with type 2 diabetes

Zwakenberg and colleagues at University Medical Center Utrecht reported, in the American Journal of Clinical Nutrition in 2019, a 6-month trial in which 35 patients with type 2 diabetes and cardiovascular disease were assigned to 360 µg MK-7 daily and 33 to placebo.12 In the MK-7 group 33 completed follow-up, and in the placebo group 27.12 The primary measure was femoral artery 18F-NaF PET activity as target-to-background ratio (TBR), with CT calcification mass as a secondary outcome.12 On PET, TBR "tended to increase in the MK-7 group compared with placebo (0.25; 95% CI: -0.02, 0.51; P = 0.06), although this was not significant".12 CT calcification mass did not increase with MK-7 compared with placebo (P = 0.18).12 In a sensitivity analysis that excluded 3 participants with no baseline calcification, calcification mass significantly increased (model 1: 0.22; 95% CI 0.04 to 0.41; P = 0.02).12 Levels of dp-ucMGP fell with MK-7 by 205.6 pmol/L (95% CI -255.8 to -155.3) compared with placebo after 3 months.12 The authors write that "this study does not support that MK-7 supplementation inhibits vascular calcification".12 Their stated limitations include that "The dropout rate was relatively high, especially in the placebo group", and that calcification mass at baseline "was higher in the MK-7 group than in the placebo group, despite randomization".12 The paper reports "No adverse events were reported" in its results summary and "No serious adverse events were reported" in the text.12 The text states that "None of the authors reported a conflict of interest related to this study", and a grant from the Dutch Heart Foundation supports two of the authors; the text read names no study-level funder.12

Deeper analysis: AVADEC

Diederichsen and colleagues reported AVADEC in Circulation in 2022, a randomised, double-blind, multicentre trial in which 365 men from the community with an aortic valve calcification (AVC) score above 300 AU were randomised to 720 µg MK-7 plus 25 µg vitamin D daily or matching placebo for 24 months.1 The primary outcome was "the change in AVC score from baseline to 24 months".1 The mean increase in AVC score was 275 AU (95% CI, 225-326 AU) with MK-7 plus vitamin D and 292 AU (95% CI, 246-338 AU) with placebo, and the mean difference in progression was 17 AU (95% CI, -86 to 53 AU; P=0.64).1 Secondary results: aortic valve area changed by 0.02 cm2 (P=0.78) and peak aortic jet velocity by 0.04 m/s (P=0.21), the latter an outcome "included as an outcome after registration of the trial", and aortic and coronary artery calcification progression "was not significantly different" between groups.1 The authors add that treatment with vitamin K2 and vitamin D "may increase the degree of aortic calcification (against hypothesis), but decrease progression of coronary arterial calcification (in favor of hypothesis)", with nonsignificant differences.1 Safety outcomes showed "no difference in the rate of heart valve surgery (1 versus 2 patients; P=0.99), all-cause death (1 versus 4 patients; P=0.37), or cardiovascular events (10 versus 10 patients; P=0.99)", and the authors write that MK-7 plus vitamin D "was generally well tolerated".1 The authors state: "we acknowledge that the negative findings could be caused by an insufficient dose, a too short follow-up period, a lack of power, or a combination of these".1 Other stated limitations: "Of 660 eligible patients, 389 accepted randomization, and 333 of those completed the study, thus less than the original planned sample size of 354", the expected treatment effect was 20% (80 versus 100 AU) against an observed 6% (275 versus 292 AU), and "the external validity is limited to men aged 65 to 74 years".1 Because the active tablet combined MK-7 with vitamin D, the trial does not separate the effect of MK-7 from that of vitamin D.1 Funding: "Supported by unrestricted grants from the Danish Heart Foundation", the Region of Southern Denmark's Research Council and the Novo Nordisk Foundation; the tablets were "provided free of charge by Kappa Bioscience, Norway, and Orkla Care, Denmark"; and "The funders had no influence on the design or conduct of the trial".1 The disclosures state that "Dr Diederichsen reports having served as an expert on a Generally Recognized as Safe panel to review the safety of the MK-7 and its proposed use in foods in the United States".1

Deeper analysis: VitaK-CAC

Vossen and colleagues at Maastricht University Medical Center reported VitaK-CAC in JAMA Cardiology in 2026, a randomised placebo-controlled trial in symptomatic patients with a coronary artery calcification (CAC) score of 50 to 400 AU, given 360 µg MK-7 daily or identical placebo for 2 years at 1 university hospital and 1 community-dwelling hospital in the Netherlands.13 Of 180 patients randomised (90 per group), 85 received MK-7 and 82 received placebo.13 The primary outcome was "the evolution of the CAC score and calcium mass at 1 and 2 years of follow-up", analysed with a generalized estimation equations model adjusted for covariates.13 Median CAC scores rose from 145 to 173 to 214 AU with placebo and from 135 to 150 to 184 AU with MK-7 at baseline, year 1 and year 2, and "The difference between the groups was significant (P = .02), even after adjustment for covariates"; the record says "A similar result was seen for calcium mass".13 The record states "No significant adverse effects were observed".13 The authors conclude that MK-7 for 2 years "may slow calcification in noncalcified plaques of patients with symptomatic CAD" and that "The clinical significance of this finding in terms of plaque stability remains to be determined".13 The full text is not open in PubMed Central, so the authors' limitations section was not read; the PubMed record does not name a funder.13 The conflict statement says "Prof Schurgers reported receiving grants from Gnosis by Lesaffre and holding shares in Coagulation Profile outside the submitted work".13 The registry entry names Maastricht University Medical Center as organisation and lists an inclusion criterion of "Baseline Agatston calciumscore 100 - 400", whereas the paper reports 50 to 400 AU.5 The registry lists Maastricht University Medical Center as lead sponsor and VitaK as a collaborator.5

The app lists a typical dose of 90 to 200 mcg/day. A search of DailyMed for "menaquinone-7 vitamin K2" returned 0 labels, so no label dose is given here.

Table 5.1Doses reported in studies and on labels9 rows
SourceDose and formPeople and length
App's figure (typical dose)90 to 200 mcg/day, oralNot tied to a single study
Knapen and colleagues 2013 and 20154,7180 µg MK-7 daily, capsules244 healthy postmenopausal women, 3 years
Emaus and colleagues 20108360 µg MK-7 as natto capsules334 healthy women aged 50 to 60 years, 12 months
Rønn and colleagues 2016 and 20219,10375 µg MK-7, with calcium and vitamin D (given daily in the 2021 trial)Women with osteopenia, 12 months (148 women) and 3 years (142 women)
RenaKvit, Levy-Schousboe and colleagues 202311360 µg MK-7 daily, one tablet123 adults on chronic dialysis, 2 years
Zwakenberg and colleagues 201912360 µg MK-7 daily68 men and women with type 2 diabetes and cardiovascular disease, 6 months
VitaK-CAC, Vossen and colleagues 202613360 µg MK-7 daily180 symptomatic patients with CAC score 50 to 400 AU, 2 years
AVADEC, Diederichsen and colleagues 20221720 µg MK-7 plus 25 µg vitamin D daily, tablet365 men with aortic valve calcification, 24 months
Du and colleagues 20236Single 1 mg dose of MK-7, fasting5 and 12 healthy men in two studies

In RenaKvit, 110 participants had 968 adverse events and 90 had 481 serious adverse events across both arms, and the number of participants with an event did not differ between groups.11 The US Pharmacopeial Convention review concluded that MK-7 as a dietary supplement "is not associated with any serious risk to health or with other public health concerns", after reviewing "nonclinical toxicity data" and "data on clinical outcomes related to safety".2 Schurgers and colleagues state that "preparations supplying 50 mug/d or more of MK-7 may interfere with oral anticoagulant treatment in a clinically relevant way".3

The app lists no markers to monitor for this compound. In Rønn and colleagues 2016, undercarboxylated osteocalcin fell by 65.6% with MK-7 against 6.4% with placebo at 3 months.9 In the 2021 report it fell by 65.2 ± 23.5% with MK-7 against 0.03 ± 38.5% with placebo after 1 year.10 Levels of dp-ucMGP changed by -212 pmol/L with MK-7 plus vitamin D versus 45 pmol/L with placebo in AVADEC, were 205.6 pmol/L lower with MK-7 than with placebo after 3 months in Zwakenberg and colleagues, and were 50% lower than with placebo in the 2015 Knapen report.1,12,7

8

Regulatory and anti-doping status

The US Pharmacopeial Convention developed monographs setting quality standards for MK-7 as a dietary ingredient and as a dietary supplement.2 The Knapen 2013 paper states that EFSA accepted a health claim on vitamin K's role in maintenance of normal bone.4 A DailyMed search for "menaquinone-7 vitamin K2" returned 0 labels. The 2026 WADA Prohibited List "shall come into effect on 1 January 2026", and a search of its text for "vitamin K", "menaquinone" and "phylloquinone" returned no match.15

Lees and colleagues write that the conclusions of their meta-analysis "are limited by small numbers of studies with substantial heterogeneity", and the review pooled trials of vitamin K supplementation without naming MK-7 in its PubMed record, so its result is not specific to MK-7.14 Two trials in healthy postmenopausal women reached different results on bone loss.4,8 Knapen and colleagues say that extrapolation of their result to children and men "needs further investigation".4 The sources do not settle the dose: AVADEC's authors name "an insufficient dose" as a possible reason for its null result, and RenaKvit's authors write that "we cannot exclude a more pronounced effect if a higher dosage of MK-7 had been used".1,11 The Du and Schurgers records give the half-life of MK-7 as "very long" with no number, so the app's 72 hours is compared here only with the 68 hours the AVADEC authors cite.6,3,1

What is the half-life of vitamin K2 (MK-7)?

The app lists a half-life of about 72 hours, and the AVADEC authors cite 68 hours for MK-7.1 Schurgers and colleagues describe it as "very long" in healthy volunteers.3

How long does MK-7 take to reach its peak level?

The app lists about 6 hours, and Du and colleagues report peak plasma concentrations at about 6 h after a single 1 mg dose.6 Schurgers and colleagues report peak serum concentrations at 4 hours after intake.3

Is vitamin K2 (MK-7) banned by WADA?

MK-7 is not named in the text of the 2026 WADA Prohibited List that was searched.15

What is the bioavailability of MK-7?

The app lists 80%, and no record read states that figure.2 The US Pharmacopeial Convention review says MK-7 has greater bioavailability than other forms of vitamin K, and the AVADEC authors give MK-7 absorption as 100%.2,1

Did MK-7 change bone density in trials?

Results differed between trials.4,10,11 A trial in 244 healthy postmenopausal women reported a smaller decline at the lumbar spine and femoral neck but not at the total hip, a trial in 334 healthy women found no difference in bone loss rates at any site after 12 months, a trial in 142 women with osteopenia reported no difference from placebo at any site, and in 123 dialysis patients 1/3 distal radius loss was accelerated with MK-7 in the intention-to-treat analysis (not confirmed in per protocol analysis) while lumbar spine BMD was maintained with MK-7 and decreased with placebo.4,8,10,11

Did MK-7 change aortic valve calcification in the AVADEC trial?

MK-7 plus vitamin D did not change aortic valve calcification progression in 365 men over 24 months.1

Did MK-7 change coronary calcification in the VitaK-CAC trial?

Median coronary calcium scores rose less with MK-7 than with placebo in 180 randomised patients over 2 years, with a between-group difference of P = .02 after adjustment.13

Does MK-7 interact with warfarin?

Schurgers and colleagues state that preparations supplying 50 µg a day or more of MK-7 may interfere with oral anticoagulant treatment in a clinically relevant way.3 RenaKvit and the VitaK-CAC registry entry excluded people on vitamin K antagonists.11,5

12

References

  1. Diederichsen ACP, et al. Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial. Circulation 2022. PMID 35465686
  2. Marles RJ, Roe AL, Oketch-Rabah HA. US Pharmacopeial Convention safety evaluation of menaquinone-7, a form of vitamin K. Nutr Rev 2017. PMID 28838081
  3. Schurgers LJ, et al. Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7. Blood 2007. PMID 17158229
  4. Knapen MH, et al. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int 2013. PMID 23525894
  5. ClinicalTrials.gov. NCT01002157. The Effects of Vitamin K2 Supplementation on the Progression of Coronary Artery Calcification (VitaK-CAC). NCT01002157
  6. Du F, et al. The study of bioavailability and endogenous circadian rhythm of menaquinone-7, a form of vitamin K2, in healthy subjects. Br J Nutr 2023. PMID 37132123
  7. Knapen MH, et al. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial. Thromb Haemost 2015. PMID 25694037
  8. Emaus N, et al. Vitamin K2 supplementation does not influence bone loss in early menopausal women: a randomised double-blind placebo-controlled trial. Osteoporos Int 2010. PMID 19937427
  9. Rønn SH, et al. Vitamin K2 (menaquinone-7) prevents age-related deterioration of trabecular bone microarchitecture at the tibia in postmenopausal women. Eur J Endocrinol 2016. PMID 27625301
  10. Rønn SH, et al. The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial. Osteoporos Int 2021. PMID 33030563
  11. Levy-Schousboe K, et al. Vitamin K supplementation and bone mineral density in dialysis: results of the double-blind, randomized, placebo-controlled RenaKvit trial. Nephrol Dial Transplant 2023. PMID 36460034
  12. Zwakenberg SR, et al. The effect of menaquinone-7 supplementation on vascular calcification in patients with diabetes: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2019. PMID 31387121
  13. Vossen LM, et al. Two Years of Menaquinone-7 Supplementation and Coronary Artery Calcification: A Randomized Clinical Trial. JAMA Cardiol 2026. PMID 42268593
  14. Lees JS, et al. Vitamin K status, supplementation and vascular disease: a systematic review and meta-analysis. Heart 2019. PMID 30514729
  15. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list